<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976816</url>
  </required_header>
  <id_info>
    <org_study_id>LBVTIMTED</org_study_id>
    <nct_id>NCT04976816</nct_id>
  </id_info>
  <brief_title>Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease</brief_title>
  <official_title>Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of local injections of two different types of steroid (betamethasone&#xD;
      suspension versus triamcinolone acetate) in management of patients with thyroid-related upper&#xD;
      lid retraction either isolated or associated with proptosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid Eye Disease (TED) is a complex autoimmune disorder that causes substantial morbidity.&#xD;
      It can result in enlargement and scarring of orbital fat and muscles with orbital&#xD;
      disfigurement, diplopia, and even vision loss. Although the disease is self-limited following&#xD;
      an inflammatory phase of 12 - 18 months, its long-term changes to periocular tissues may have&#xD;
      a significant effect on the quality of life, mental health, and socioeconomic status of&#xD;
      patients.&#xD;
&#xD;
      Most patients with TED (&gt;90%) have Graves' disease, which is an inflammatory autoimmune&#xD;
      condition that is caused by thyrotropin (TSH) receptor autoantibodies. Graves' disease is&#xD;
      common around the world and it mainly affects middle-aged women with an overall prevalence of&#xD;
      0.5%.&#xD;
&#xD;
      Several validated assessment scores are used to assess different components of the disease.&#xD;
      The two main current TED classifications are from the European Group on Graves Orbitopathy&#xD;
      (EUGOGO); and Vision, Inflammation, Strabismus, Appearance (VISA). EUGOGO has introduced one&#xD;
      score for clinical activity (CAS) and one for severity &quot;Clinical Severity Score&quot; (CSS). The&#xD;
      baseline CAS asses 7 subjective symptoms and inflammatory signs with 3 additional points in&#xD;
      follow-up for increased proptosis, decreased ocular motility, or decreased visual acuity (the&#xD;
      CAS 10- point scale). In comparison, CSS evaluates the magnitude of the exophthalmometer or&#xD;
      proptosis values, lid retraction, diplopia grades, and corneal involvement.&#xD;
&#xD;
      Periorbital inflammation can cause swelling, fatty infiltration, and scarring of the eyelid&#xD;
      muscles, resulting in eyelid retraction and upper scleral exposure, which are the most common&#xD;
      clinical features of TED.&#xD;
&#xD;
      Several treatment options have been described for correction of eyelid retraction (ELR),&#xD;
      including local steroid, Botox and filler injection, and surgeries in the fibrotic stage.&#xD;
      Although surgical treatment remains an effective option, the outcomes may be unpredictable.&#xD;
      In addition, there are some situations where surgery is inappropriate or contraindicated,&#xD;
      where temporary or definitive measures are required during the active phase of the disease,&#xD;
      or where patients may prefer less invasive options.&#xD;
&#xD;
      Systemic steroid therapy is a well-established form of immunosuppressive treatment for TED.&#xD;
      There have been reports showing promising results with local steroid injection for the&#xD;
      treatment of upper eyelid retraction (UER), There are also some reports about the retrobulbar&#xD;
      and periocular injection of steroids for management of proptosis in TED.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to measure the change in MRD1 in mm using a ruler in all groups after peri-levator injection of different types of steroid</measure>
    <time_frame>2 minutes</time_frame>
    <description>The technique will be considered; 1) Effective if the MRD1 reaches the normal value&lt; or= 4mm, 2) Partially effective if the MRD1 is improved but do not reach the normal values, 3) Ineffective if no improvement occur in MRD1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to measure the change in proptosis in mm using Hertel's exophthalmometer in group B after retrobulbar injection of different types of steroid</measure>
    <time_frame>4 minutes</time_frame>
    <description>The technique will be considered; 1) Effective if the reading of Hertel's exophthalmometer reaches the normal value (16Â±2mm), 2) Partially effective if the proptosis is improved but do not reach the normal values, 3) Ineffective of no improvement occur in proptosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to document any change in size of superior rectus levator complex and other extra-ocular muscles</measure>
    <time_frame>4 minutes</time_frame>
    <description>measuring size of superior rectus levator complex and other extra-ocular muscles before and after injections by orbital imaging techniques (CT or MRI).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Thyroid Eye Disease</condition>
  <arm_group>
    <arm_group_label>A1 peri-levator betamethasone injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with isolated thyroid-related upper lid retraction who will be given the Peri-levator injection of betamethasone suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 Peri-levator triamcinolone acetate injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with isolated thyroid-related upper lid retraction who will be given Peri-levator injection of triamcinolone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 Peri-levator and retrobulbar betamethasone injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of betamethasone suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 Peri-levator and retrobulbar triamcinolone acetate injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of triamcinolone acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peri-levator betamethasone injection</intervention_name>
    <description>The injection dose will be 1.5 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate &amp;2 mg betamethasone sodium phosphate). The needle will be introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection is delivered. The injection will be repeated every 4-6 weeks according to the clinical response up to 3 injections.</description>
    <arm_group_label>A1 peri-levator betamethasone injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peri-levator triamcinolone injection</intervention_name>
    <description>The needle will be introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate is injected. The injection will be repeated every 4-6 weeks according to the clinical response up to 3 injections.</description>
    <arm_group_label>A2 Peri-levator triamcinolone acetate injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peri-levator and retrobulbar betamethasone injection</intervention_name>
    <description>In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis will be given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.</description>
    <arm_group_label>B1 Peri-levator and retrobulbar betamethasone injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peri-levator and retrobulbar triamcinolone injection</intervention_name>
    <description>In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis will be given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.</description>
    <arm_group_label>B2 Peri-levator and retrobulbar triamcinolone acetate injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Thyroid Eye Disease.&#xD;
&#xD;
          -  Thyroid function within normal range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on systemic steroid and or immunosuppressive therapy.&#xD;
&#xD;
          -  Patients underwent thyroidectomy.&#xD;
&#xD;
          -  Sight threatening (severe) TED which requires immediate surgery.&#xD;
&#xD;
          -  Patients with fibrotic ocular muscles who need surgery.&#xD;
&#xD;
          -  Contraindications to steroid therapy as in pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Abdelal, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Shehata, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salma Kedwany, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rawda Abdelnasser, MD</last_name>
    <phone>00201008053325</phone>
    <email>rawda878@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016 Aug 27;388(10047):906-918. doi: 10.1016/S0140-6736(16)00278-6. Epub 2016 Mar 30. Review.</citation>
    <PMID>27038492</PMID>
  </reference>
  <reference>
    <citation>Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018 May;14(5):301-316. doi: 10.1038/nrendo.2018.18. Epub 2018 Mar 23. Review.</citation>
    <PMID>29569622</PMID>
  </reference>
  <reference>
    <citation>Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2.</citation>
    <PMID>27099835</PMID>
  </reference>
  <reference>
    <citation>Kazim M, Gold KG. A review of surgical techniques to correct upper eyelid retraction associated with thyroid eye disease. Curr Opin Ophthalmol. 2011 Sep;22(5):391-3. doi: 10.1097/ICU.0b013e3283499433. Review.</citation>
    <PMID>21730842</PMID>
  </reference>
  <reference>
    <citation>Xu D, Liu Y, Xu H, Li H. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Can J Ophthalmol. 2012 Feb;47(1):34-41. doi: 10.1016/j.jcjo.2011.12.005.</citation>
    <PMID>22333849</PMID>
  </reference>
  <reference>
    <citation>Hamed-Azzam S, Mukari A, Feldman I, Saliba W, Jabaly-Habib H, Briscoe D. Fornix triamcinolone injection for thyroid orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2015 May;253(5):811-6. doi: 10.1007/s00417-015-2957-7. Epub 2015 Feb 12.</citation>
    <PMID>25673253</PMID>
  </reference>
  <reference>
    <citation>Joos ZP, Sullivan TJ. Peri-levator palpebrae superioris triamcinolone injection for the treatment of thyroid eye disease-associated upper eyelid retraction. Clin Exp Ophthalmol. 2017 Aug;45(6):651-652. doi: 10.1111/ceo.12939. Epub 2017 Mar 28.</citation>
    <PMID>28248444</PMID>
  </reference>
  <reference>
    <citation>Poonyathalang A, Preechawat P, Charoenkul W, Tangtrakul P. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. J Med Assoc Thai. 2005 Mar;88(3):345-9.</citation>
    <PMID>15962642</PMID>
  </reference>
  <reference>
    <citation>Bagheri A, Abbaszadeh M, Yazdani S. Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy. J Ophthalmic Vis Res. 2020 Feb 2;15(1):69-77. doi: 10.18502/jovr.v15i1.5948. eCollection 2020 Jan-Mar. Review.</citation>
    <PMID>32095211</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Du B, Yang M, Zhu Y, He W. Peribulbar injection of glucocorticoids for thyroid-associated ophthalmopathy and factors affecting therapeutic effectiveness: A retrospective cohort study of 386 cases. Exp Ther Med. 2020 Sep;20(3):2031-2038. doi: 10.3892/etm.2020.8896. Epub 2020 Jun 17.</citation>
    <PMID>32782513</PMID>
  </reference>
  <results_reference>
    <citation>Smith TJ, HegedÃ¼s L. Graves' Disease. N Engl J Med. 2016 Oct 20;375(16):1552-1565. Review.</citation>
    <PMID>27797318</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Rawda Abdelnaser</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

